<DOC>
	<DOCNO>NCT00976131</DOCNO>
	<brief_summary>This research study hop examine effect Coenzyme Q10 doxorubicin ( Adriamycin ) metabolism breast cancer treatment .</brief_summary>
	<brief_title>Study CoQ10 During One Cycle Doxorubicin Treatment Breast Cancer</brief_title>
	<detailed_description>Doxorubicin lifesaving breast cancer treatment . However , approximately 3-20 % woman receive doxorubicin treatment experience damage heart muscle . Coenzyme Q10 fat soluble antioxidant dietary supplement may protect heart damage doxorubicin treatment . It unknown Coenzyme Q10 may interact doxorubicin . This study assess effect Coenzyme Q10 doxorubicin metabolism . This phase I randomize , placebo-controlled , cross-over pharmacokinetic dose-finding study assess safety CoQ10 doxorubicin treatment breast cancer . Safety assess measure 1 ) intra-patient difference doxorubicin active metabolite , without CoQ10 , 2 ) adverse event . We hypothesize CoQ10 administration doxorubicin treatment safe affect doxorubicin active metabolite . Using three dose level CoQ10 , maximum tolerate dose ( MTD ) determine assess change doxorubicin concentration ( area curve ( AUC ) , change peak concentration level ( Cmax ) ) , adverse event .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Coenzyme Q10</mesh_term>
	<mesh_term>Ubiquinone</mesh_term>
	<criteria>Diagnosis early stage breast cancer ( stage I , II , III ) ; Scheduled receive least four round dose dense doxorubicin therapy neoadjuvant adjuvant setting ; No history prior chemotherapy , radiation , hormonal therapy previous 5 year ; For woman receive adjuvant therapy , single lumen implant venous access device ( i.e . single port ) unilateral cancer double lumen implant venous access device ( i.e . double port ) bilateral breast cancer Age 21 year old ; ECOG performance status ≤ 2 ( Karnofsky &gt; 60 % ) ; Normal organ marrow function define : Leukocytes ≥ 3,000/uL , Absolute neutrophils count ( ANC ) ≥ 1,500/uL baseline , Platelets ≥ 100,000/uL , Total bilirubin ≤ 1.5 X normal institutional limit , AST ( SGOT ) /ALT ( SGPT ) ≤ 2.5 X institutional ULN , Serum creatinine within normal institutional limit ; Left ventricular ejection fraction &gt; 55 % ; No history CoQ10 supplement use within 30 day initiate study drug ; No uncontrolled significant comorbid illness ; Not pregnant , breastfeed , plan become pregnant course study ; Willingness comply study intervention followup procedure ; Ability speak English Spanish ; Ability provide inform consent . Inability understand unwillingness sign write informed consent document ; Any significant toxic side effect relate first second dose doxorubicin/cyclophosphamide chemotherapy biologic therapy resolve less CTCAE 3.0 grade 3 nonhematological toxicity ; Currently use investigational agent ; Unstable severe intercurrent medical condition , opinion investigator , might interfere participant 's ability follow protocol achieve study objective ; Psychological sociological condition , addictive disorder , family problem would preclude adherence study drug compliance protocol Women report pregnancy , breast feeding , positive pregnancy test ; Use CoQ10 supplement use within 30 day initiate study drug ; Use overthecounter nutritional vitamin great 5x RDA ; Fish allergy ( due fishbased softgel shell ) ; Currently take FDA cardioprotective drug , Zinecard ( dexrazoxane ) ; History chronic hepatitis B , hepatitis C , HIV infection ; Problems swallow oral medication due prolong emesis , mucositis , esophageal dysfunction , etc . ; , Currently take form antioxidant supplement study . Use warfarin . Kosher ( due fishbased softgel shell ) Dietary restriction tilapia ( due tilapia fishbased softgel shell ) Titanium Dioxide allergy ( due opaque color use softgel ) .</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Early Stage Breast Cancer</keyword>
	<keyword>Complementary Alternative Medicine</keyword>
	<keyword>CAM</keyword>
</DOC>